Multicenter prospective observation study of salvage-line bevacizumab for unresectablemetastatic colorectal cancer in Okayama

Multicenter prospective observation study of salvage-line bevacizumab for unresectablemetastatic colorectal cancer in Okayama - MAYUMI trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010955

Enrollment

Registered

2013-06-13

Start date

2013-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Unresectable/recurrent colorectal cancer patients, who are refractory or intolerable to oxaliplatin and irinotecan, intended to recieve any chemotherapies with bevacizumab. 2. Evaluable of the effectiveness of the treatment by image. 3. Evaluable of the safty of the treatment. 4. Be able to provide a clinical examination information. 5. Be able to do the following treatement, any chemotharapise with Bevacizumab 2.5mg/kg/week or 5.0mg/kg/week.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
PFS; progression-free survival	—

Secondary

Measure	Time frame
OS; overall survival TTF; time to treatment-failure ORR; overall response rate Safty	—

Countries

Japan

Contacts

Public ContactTakeshi Nagasaka

Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Department of Gastroenterological Surgery

086-235-7257

Outcome results